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ABSTRACT
To this date, the criteria to distinguish peritoneal macrophages and dendritic cells (DCs) 
are not clear. Here we delineate the subsets of myeloid mononuclear cells in the mouse 
peritoneal cavity. Considering phenotypical, functional, and ontogenic features, peritoneal 
myeloid mononuclear cells are divided into 5 subsets: large peritoneal macrophages (LPMs), 
small peritoneal macrophages (SPMs), DCs, and 2 MHCII+CD11c+CD115+ subpopulations 
(i.e., MHCII+CD11c+CD115+CD14−CD206− and MHCII+CD11c+CD115+CD14+CD206+). Among 
them, 2 subsets of competent Ag presenting cells are demonstrated with distinct functional 
characteristics, one being DCs and the other being MHCII+CD11c+CD115+CD14−CD206− cells. 
DCs are able to promote fully activated T cells and superior in expanding cytokine producing 
inflammatory T cells, whereas MHCII+CD11c+CD115+CD14−CD206− cells generate partially 
activated T cells and possess a greater ability to induce Treg under TGF-β and retinoic acid 
conditions. While the development of DCs and MHCII+CD11c+CD115+CD14−CD206− cells 
are responsive to the treatment of FLT3 ligand and GM-CSF, the number of LPMs, SPMs, 
and MHCII+CD11c+CD115+CD14+CD206+ cells are only influenced by the injection of GM-
CSF. In addition, the analysis of gene expression profiles among MHCII+ peritoneal myeloid 
mononuclear cells reveals that MHCII+CD11c+CD115+CD14+CD206+ cells share high similarity 
with SPMs, whereas MHCII+CD11c+CD115+CD14−CD206− cells are related to peritoneal 
DC2s. Collectively, our study identifies 2 distinct subpopulations of MHCII+CD11c+CD115+ 
cells, 1) MHCII+CD11c+CD115+CD14−CD206− cells closely related to peritoneal DC2s and 2) 
MHCII+CD11c+CD115+CD14+CD206+ cells to SPMs.
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INTRODUCTION
Mononuclear phagocytes such as dendritic cells (DCs) and macrophages are essential in 
orchestrating immune responses and maintaining tissue homeostasis. In almost all tissues 
and organs, they efficiently take up Ags and thus effectively induce immune responses against 
Ags. Despite some similarities in recognizing and capturing Ags, DCs and macrophages play 
quite a different role in innate and adaptive immune responses (1,2). DCs are specialized 
immune cells function as both sentinels and Ag-presenting cells (APCs). DCs pick up Ags in 
periphery and migrate to draining lymph nodes where DCs present Ag-processed peptides as 
epitopes on MHC molecules to responding T cells. Depending upon the immune context in 
which the Ags are captured, DCs can trigger either immunity or tolerance (3). Macrophages 
are multifunctional cells that promote the initiation, progression, and resolution of 
inflammation (4,5). Compared to DCs, macrophages are highly phagocytic and thus mainly 
focus on the rapid elimination of phagocytosed Ags. By quickly phagocytosing and clearing 
Ags such as microorganisms and cell debris, they contribute to maintaining local tissue 
integrity. Macrophages also promote the resolution of inflammatory process by inducing 
angiogenesis and tissue repair. Macrophages and DCs are morphologically different; 
adherent macrophages display large irregular shapes while non-adherent DCs exhibit long 
probing processes or dendrites (6).
Besides the differences described above, macrophages and DCs are distinguished by 
their distinctive surface markers, such as high levels of F4/80 (F4/80hi) for macrophages 
and high level of CD11c (CD11chi) for DCs, respectively (7,8). However, recent advances in 
the techniques of multi-parameter cell analysis have revealed the complexity of surface 
markers for respective cells. As a result, both macrophages and DCs are deemed to have 
heterogeneous populations which vary between different tissues and organs (1,9-13). For 
example, mouse lung alveolar macrophages and gut lamina propria macrophages express 
CD11c and MHC II (9-12) which are 2 of the signature markers for DCs, whereas epidermal 
Langerhans cells express F4/80, a prominent marker for macrophages (13). Therefore, 
it is important to establish tissue-specific strategies to accurately differentiate distinct 
subpopulations of macrophages and DCs.
Peritoneal cavity is a specialized compartment formed between the parietal peritoneum and 
visceral peritoneum. Not only multiple organs and circulatory systems but also a variety of 
immune cells are found in the peritoneal cavity where local and systemic immune responses 
occur dynamically (14,15). Mononuclear phagocytes, mainly macrophages, comprise almost 
half of all peritoneal immune cells. Macrophages in the mouse peritoneal cavity consist of 
2 major subsets: large peritoneal macrophages (LPMs) and small peritoneal macrophages 
(SPMs). LPMs, the most abundant mononuclear phagocytes in the peritoneal cavity, are 
long-lived self-renewing cells originating from yolk sac progenitors and express F4/80hi 
(16,17). Although SPMs are much less abundant in steady state, their number increases 
during inflammation. SPMs are short-lived cells that differentiate from circulating 
monocytes that express high levels of MHC II but low levels of F4/80 (16,18,19). Since the 
high expression of MHC II is a key feature of DCs, distinguishing DCs and SPMs based on 
their surface markers is not clearly defined and somewhat ambiguous. Some investigators 
used the CD11chi as a prerequisite for defining peritoneal DCs and thus excluded all the 
CD11chi cells from peritoneal SPMs (16,20,21), while others categorized the peritoneal 
macrophages without considering their expression of CD11c and excluded all the CD115+ 
cells from peritoneal DCs (19,22). Since cells expressing both CD11c and CD115 are present 
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in the peritoneal cavity (17), it is needed to characterize whether those cells are a subset (s) 
of SPMs or DCs.
In this report, we classify the mouse peritoneal myeloid mononuclear cells into 5 
populations: LPMs, SPMs, DCs, and 2 subpopulations of MHCII+CD11c+CD115+ cells. 
According to our examinations, 2 out of these 5 populations, i.e., DCs and one of the 
MHCII+CD11c+CD115+ subpopulations were able to present Ags to T cells efficiently. 
The potent Ag-presenting MHCII+CD11c+CD115+ subpopulation was identified as CD14−
CD206− whereas the incompetent Ag-presenting MHCII+CD11c+CD115+ subpopulation 
was identified as CD14+CD206+. Although both subsets of APCs in the peritoneal cavity 
strongly stimulated T cells, DCs were more effective in inducing fully activated and cytokine 
producing inflammatory T cells, but MHCII+CD11c+CD115+CD14−CD206− subset possessed 
superior capacity to induce Treg. In development, the numbers of both peritoneal DCs 
and MHCII+CD11c+CD115+CD14−CD206− subset were similarly influenced by FLT3 ligand 
(FLT3L) and GM-CSF, while the MHCII+CD11c+CD115+CD14+CD206+ population was strongly 
affected by GM-CSF but not by FLT3L. In addition, the analysis of gene expression profiles 
indicates that MHCII+CD11c+CD115+CD14−CD206− cells are closely related to peritoneal DC2 
subset, whereas MHCII+CD11c+CD115+CD14+CD206+ cells are indistinguishable from SPMs. 
Therefore, our present study clearly demonstrates that peritoneal MHCII+CD11c+CD115+ cells 
are divided into 2subpopulations: one closely related to DCs and the other to SPMs.
MATERIALS AND METHODS
Animals
C57BL/6 mice were purchased from Orient Bio (Seongnam, Korea), and OT-1, OT-2, and 
GM-CSF−/− mice were from the Jackson Laboratory (Bar Harbor, ME, USA). FLT3−/− mice were 
a gift from Professor Jae-Hoon Choi in Hanyang University. All animals were maintained and 
bred in specific pathogen-free facilities in the Yonsei University College of Medicine. Female 
mice between 8 and 12 wk of age were used in all experiments. Animal care and experiments 
were performed according to the guidelines and protocol (#2016-0040) approved by the 
Institutional Animal Care and Use Committees of the Yonsei University College of Medicine.
Abs and reagents
Fluorochrome-conjugated mAbs to CD3, CD19, Ly6G, intercellular adhesion molecule 2 
(ICAM2), MHCI, MHCII, CD11b, CD11c, CD115, XCR1, CD172a, 33D1, F4/80, CD14, CD206, 
CD24, CD8, CD4, Va2, CD25, CD69, CD44, CD62L, IFN-γ, IL-4, IL-17a, forkhead box P3 
(FOXP3), CX3CR1, CD64, CD226, CD68, CD207, CD103, CD209a, CD209b, Ly6C, Clec9a, 
CD205, CD117, CD135, B220, PD-1, PD-L1, CCR2, CD40, CD80, CD86, CCR7, sialic acid binding 
Ig-like lectin F, and high-affinity IgE receptor were purchased from BioLegend (San Diego, CA, 
USA). PE-conjugated anti-CD207 and PE-Cyainine7-conjugated anti-proto-oncogene tyrosine-
protein kinase MER were purchased from eBioscience (San Diego, CA, USA). CellTrace™ 
CFSE or CellTrace™ violet (CTV) Cell Proliferation Kits and LIVE/DEAD™ Fixable Yellow or 
Far Red Dead Cell Stain Kits were purchased from Thermo Fisher Scientific Korea (Seoul, 
Korea) and were used according to the instructions provided by the manufacturers. Ovalbumin 
(OVA; Sigma-Aldrich, St. Louis, MO, USA), FITC-conjugated OVA (FITC-OVA; Thermo 
Fisher Scientific Korea), and Fluoresbrite® yellow green microspheres (YGM) 1.00 μm beads 
(Polysciences, Warrington, PA, USA) were purchased respectively. LPS and all trans-retinoic 
acid were purchased from Sigma-Aldrich; human TGF-β1 from Peprotech (Rocky Hill, NJ, USA); 
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mouse IL-4, mouse IL-6, and anti-mouse IFN-γ neutralizing mAb from BioLegend; PMA and 
ionomycin from LC Laboratories (Woburn, MA, USA). Cells were cultured in DMC7 medium 
(23) composed of DMEM containing L-glutamine, high glucose, and pyruvate (GE Healthcare 
Life Sciences, Logan, UT, USA) and 7% fetal calf serum (GE Healthcare Life Sciences) 
supplemented with 1× solutions of non-essential amino acids (GE Healthcare Life Sciences) and 
antibiotic-antimycotic (GE Healthcare Life Sciences). Mouse M-CSF, GM-CSF, and FLT3L were 
produced and purified in house as described previously (23-25).
Flow cytometry
Peritoneal exudate cells were harvested by lavage with 5 ml cold PBS containing 3% fetal 
calf serum. Single cell suspensions were blocked with neat culture supernatant of 2.4G2 (Fc 
blocking) mAb hybridoma and washed with FACS buffer (2% FCS, 2 mM EDTA, 0.1% sodium 
azide). Then, the samples were incubated with the appropriate mixture of fluorochrome-
conjugated mAbs and dead cell staining dye for 30 min at 4°C and washed twice with FACS 
buffer. The mixture of mAbs against lineage (Lin) makers of differentiated cells consisted of 
anti-CD3, anti-CD19, and anti-Ly-6G. Surface-stained cells were resuspended in Fixation/
Permeabilization solution (BioLegend) prior to staining intracellular cytokines. Each sample 
was analyzed with FACSVerse™ and LSRFortessa™ flow cytometer (BD Biosciences, San Jose, 
CA, USA) or sorted with FACSAria™ II cell sorter (BD Biosciences) at the Flow Cytometry Core 
of the Yonsei Biomedical Research Institute in the Yonsei University College of Medicine. Flow 
cytometric data were analyzed with FlowJo software (FlowJo, Ashland, OR, USA).
Ag uptake
Mice were injected intraperitoneally (i.p.) with 200 μg of FITC-OVA or 200 μl of 0.0027% 
YGM beads for 1 h, and peritoneal exudate cells were harvested as described above. Then, 
peritoneal exudate cells were stained for surface markers with fluorochrome-conjugated 
mAbs followed by the analysis with a flow cytometer as described above. Geometric mean 
fluorescence intensity index of the FITC channel is defined as below.
Ag presentation and T cell proliferation
Mice were injected i.p. with 1.5 mg of soluble OVA for 1 h, and peritoneal exudate cells were 
harvested as described above. Then, peritoneal exudate cells were stained with fluorochrome-
conjugated mAbs before purifying OVA-laden APCs by sorting with FACSAria™ II cell sorter. 
Splenic T cells from OT-1 and OT-2 mice were enriched by excluding CD19+, CD49b+, MHC II+, 
CD11b+, F4/80+, B220+, and CD4+ (for OT-1) or CD8+ (for OT-2) splenocytes using appropriate 
biotinylated Abs and anti-biotin Dynabeads® (ThermoFisher Scientific Korea) and labeled 
with 5 mM CFSE or CTV Cell Proliferation Kits for 10 min at 37°C. Then, CFSE or CTV labeled 
T cells were added into round bottom 96-well plates at 2.5×104/well and mixed with isolated 
APCs at an indicated APC: T cell ratio in the media containing 57.2 μM β-mercaptoethanol 
(Sigma-Aldrich). After co-culture with APCs for 3–4 days, the proliferation of live T cells was 
evaluated by the dilution of CFSE or CTV (6,26). For in vitro T-cell polarization assays, the 
mixture of APCs and T cells (APC:T cell = 1:10) included additional cytokines, neutralizing 
Abs, and reagents as follows: Th0 (media alone), Th1 (1 μg/ml LPS) (27), Th2 (10 ng/ml IL-
4) (28,29), Th17 (3 ng/ml TGF-β, 20 ng/ml IL-6) (30), iTreg (3 ng/ml TGF-β, 1 nM all-trans 
retinoic acid (ATRA); (31,32), type 0 cytotoxic T cell (Tc0) (media alone), Tc1 (1 μg/ml LPS) 
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Geometric Mean of Sample from the FITC-OVA Injected Mice − Geometric Mean of Sample from the PBS Injected MiceGeometric Mean of Sample from the PBS Injected Mice  
(33), Tc2 (10 μg/ml anti-IFN-γ, 20 ng/ml IL-4) (33), Tc17 (10 μg/ml anti-IFN-γ, 5 ng/ml TGF- 
β, 20 ng/ml IL-6) (33). After culture for 3–4 days, cells were stimulated with PMA (12 nM), 
ionomycin (1 μM), and brefeldin A (5 μg/ml) for 4 h before analysis.
Cytokine-induced cell expansion in vivo
Mice were subcutaneously injected daily with 10 μg of either mouse M-CSF, GM-CSF, or FLT3L 
for up to 5 days. The effect of mouse GM-CSF was significant enough after 3 consecutive daily 
injections. Peritoneal exudate cells were harvested and analyzed 24 h after the last injection.
RNA sequencing (RNA-Seq) and bioinformatics analysis
Peritoneal exudate cells were prepared, stained, and subjected to flow cytometric isolation 
with FACSAria™ II cell sorter as described above. Then, we isolated RNA samples from the 
respective Lin-MHCII+ peritoneal cell subsets using MiniBEST Universal RNA Extraction 
kit (TaKaRa Bio, Shiga, Japan). Subsequent procedures and analysis were performed by 
Macrogen, Inc (Seoul, Korea) as follows: reverse transcription of mRNA and generation of 
cDNA libraries were carried out with SMARTer Ultra low input RNA library kit and sequenced 
with Illumina NovaSeq. The relative abundances of gene were measured in Fragments Per 
Kilobase of exon per Million fragments mapped using StringTie. The result was statistically 
analyzed to find differentially expressed genes using the estimates of abundances for each 
gene in samples. Multidimensional scaling method was used to visualize the similarities 
among samples. The larger the dissimilarity between 2 samples, the further apart the points 
representing the experiments in the picture should be. We applied to the Euclidean distance 
as the measure of the dissimilarity. Hierarchical clustering analysis also was performed using 
complete linkage and Euclidean distance as a measure of similarity to display the expression 
patterns of differentially expressed transcripts which are satisfied with |fold change|≥2. All 
data analysis and visualization of differentially expressed genes was conducted using R 3.5.1 
(https://www.r-project.org). RNA-Seq data have been deposited in NCBI's Gene Expression 
Omnibus (GEO) and are accessible through GEO Series accession number GSE130424 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130424).
Statistical analysis
Experiments with multiplicate samples were presented as mean±SEM from at least 3 
independent experiments. Statistical comparisons between different groups were analyzed 
using unpaired Student's t-test using SigmaPlot (Systat Software, San Jose, CA, USA). Statistical 
significance is denoted by the p values equal or below 0.05 (*), 0.01 (**), 0.001 (***), and 0.0001 
(****). Data were plotted for graphs with PRISM6 (GraphPad Software, La Jolla, CA, USA).
RESULTS
Phenotypic characterization of peritoneal myeloid mononuclear cells
Myeloid mononuclear cells of the mouse peritoneal exudate cells were analyzed for the 
expression of various surface markers of DCs and macrophages using multi-parameter flow 
cytometry (Fig. 1A). Peritoneal myeloid mononuclear cells were recognized following the 
exclusion of other hematopoietic cells expressing CD3, Ly6G, and CD19. Then, the cells with 
ICAM2−MHCII− phenotypes (peritoneal eosinophils, mast cells, and monocytes) were further 
excluded (17). LPMs were identified as ICAM2+low-level MHC class II (MHCIIlo) population 
(P-I in Fig. 1A), which also expressed F4/80hi (Fig. 1B) and comprised the vast majority of 
peritoneal myeloid mononuclear cells (Fig. 1C).
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Unlike the most abundant LPMs, the other peritoneal myeloid mononuclear cells expressed 
high levels of MHC II, a typical feature of APCs. These MHCII+ cells were further divided into 
3 populations based on the expression of CD11c and CD115: CD11c+CD115− DCs (P-II), CD11c−
CD115+ SPMs (P-III), and CD11c+CD115+ population (P-IV) (Fig. 1A). The identity of CD11c+CD115+ 
P-IV subset in the peritoneal cavity has been ambiguous and classified as either DCs (16,20,21) 
or SPMs (19,22) because it expresses both markers of DCs (CD11c) and macrophages (CD115). 
To clarify the nature of P-IV cells, we further examined the levels of various markers expressed 
by DCs and macrophages, including F4/80, XCR1, 33D1, CD11b, CD14, CD24, CD172α, CD206, 
CD226, CD301b, and others (Fig.1B; not all data shown). Similar to DCs which consisted of a 
minor subset of XCR1+CD24+ DC1 and a major subset of XCR1−CD24− DC2, the result clearly 
indicated that P-IV subset was also composed of 2 phenotypically heterogeneous cells (Fig. 1B). 
Therefore, we further classified P-IV subset into 2 subpopulations, i.e., CD14−CD206− P-IV.I and 
CD14+CD206+ P-IV.II. The number of P-IV.II cells was almost twice the number of P-IV.I cells but 
similar to the number of DCs in the peritoneal cavity (Fig. 1C).
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Figure 1. Classification of peritoneal myeloid mononuclear cells. Cells in the peritoneal cavity are harvested and analyzed by multi-parameter flow cytometry. (A) 
The gating strategies to divide peritoneal myeloid mononuclear cells. Cells expressing Lin markers of CD3, CD19, and Ly6G are excluded. (B) Distinct expression 
of myeloid cell markers. P-IV subset is further divided into P-IV.I and P-IV.II based on the expression levels of CD14 and CD206 (in red box). (C) The number 
of cells in each subset is evaluated from the peritoneal cavity. Data are shown with SEM from at least 5 independent experiments. Each experiment analyzed 
peritoneal exudate cells from a single mouse. 
SSC, side scatter; FSC, forward scatter.
Characterization of morphology and Ag uptake
DCs and macrophages can be distinguished by their peculiar morphological characteristics 
(6,21,34). Mouse peritoneal exudate cells were separated into 5 subsets of myeloid mononuclear 
cells, as described above, by flow cytometric sorting and were then cultured overnight before 
examination. It was obvious that, out of these 5 populations, 3 populations, i.e., LPMs, SPMs, 
and P-IV.II cells exhibited a typical macrophage morphology, or were observed as large adherent 
cells with irregular shapes (Fig. 2A). Meanwhile, DCs and P-IV.I cells displayed a dendritic 
morphology, or were observed as non-adherent cells with long cellular processes (Fig. 2A).
DCs and macrophages are also distinguished by their different ability to take up Ags (17,34). 
Endocytic and phagocytic capacities of the 5 myeloid mononuclear cell subsets we classified 
above were evaluated within the peritoneal cavity. We injected either soluble (FITC-OVA) or 
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Figure 2. Morphology and Ag uptake ability are examined for each subset of peritoneal myeloid mononuclear cells. (A) Peritoneal exudate cells are harvested 
and sorted by flow cytometry according to the gates as in Fig. 1. Isolated cells in each subset are cultured overnight before taking pictures under 200× 
magnification. Cells in each subset are compared for their ability to take up Ags via endocytosis (B) or phagocytosis (C). (B) 200 μg of soluble FITC-conjugated 
OVA proteins are injected i.p. After 1 h, peritoneal exudate cells are harvested and analyzed. The extents of Ag uptake are assessed by the geometric mean 
fluorescence intensity index of the FITC channel. Each gray-filled histogram is from each subset in control uninjected mice. Overlay of histograms on FITC 
channel from each subset is shown on the right lower side. Representative data shown are from 2 independent experiments. (C) A volume of 200 μl of 0.0027% 
YGM (1.0 μm diameter) is injected i.p. After 1 h, peritoneal exudate cells are harvested and analyzed. Percentages of cells that phagocytose more than 1, 2, or 
3 beads are denoted in order. Overlay of histograms on YG channel from each subset is shown on the right lower side. Representative data shown are from 2 
independent experiments.
particulate (YGM) forms of fluorescently labeled Ags into the peritoneal cavity. An hour after 
injection, endocytosis of FITC-OVA or phagocytosis of YGM beads by the 5 myeloid mononuclear 
cell subsets were assessed respectively and compared to one another (Fig. 2B and C). As 
expected, LPMs were the most active in both endocytosis and phagocytosis. Compared to LPMs, 
the other populations were much poor in endocytosis and phagocytosis. However, the activities of 
both endocytosis and phagocytosis by SPMs and P-IV.II cells were similar and significantly higher 
than those by DCs and P-IV.I cells (Fig. 2B and C).
Comparison of Ag-presenting ability to stimulate naïve T cells
A key functional difference between DCs and macrophages is determined by the outcome 
of Ag uptake; i.e., DCs are efficient in processing and presenting Ags to responding T 
cells whereas macrophages are much less efficient (34,35). To evaluate the difference in 
Ag-presenting ability, soluble OVA protein was injected into the peritoneal cavity, and the 
peritoneal exudate cells were harvested after an hour and were sorted by flow cytometry 
into the subsets of myeloid mononuclear cells. Then, the subsets of cells isolated from the 
OVA-pulsed peritoneal cavity were assessed for their ability to stimulate naive T cells in vitro 
using OVA-specific OT-1 (CD8) and OT-2 (CD4) T cell receptor transgenic mice (36,37). First, 
OVA-pulsed LPMs, DCs, SPMs, and P-IV cells were separated and examined for their ability 
to stimulate CD8+ OT-1 and CD4+ OT-2 T cells. Although all the subsets of peritoneal myeloid 
mononuclear cells showed similar levels of MHC I expression (Supplementary Fig. 1), it was 
evident that DCs were most capable of cross-presenting OVA Ag and thus strongly inducing 
the proliferation of CD8+ OT-1 T cells (Fig. 3A, left panels). P-IV cells were also efficient in 
stimulating OT-1 T cells although weaker than DCs. Meanwhile, both LPMs and SPMs were 
poor in cross-presenting OVA Ag to CD8+ OT-1 T cells. Similarly, CD4+ OT-2 T cells were used 
to evaluate the Ag presentation of OVA via MHC II molecules (Fig. 3A, right panels). Among 
the MHCII+ subsets, DCs were the most potent in stimulating responding OT-2 T cells and P-IV 
cells were weaker but SPMs were very poor. However, LPMs were completely incompetent to 
induce the proliferation of OT-2 T cells even in the highest APC to T cell ratio, likely because 
of the MHCII−/lo phenotype of LPMs. These data imply that P-IV cells might contain a DC-like 
subpopulation. Therefore, we compared the Ag-presenting ability between P-IV.I and P-IV.II 
subsets (Fig. 3B). To our surprise, P-IV.I cells were able to stimulate both CD8+ OT-1 and CD4+ 
OT-2 T cells as efficiently as or better than peritoneal DCs. Meanwhile, like other peritoneal 
macrophage subsets, P-IV.II cells were unable to induce the proliferation of responding T cells.
Distinct differentiation of T cells by peritoneal APCs
We investigated the functional difference between 2 robust APCs, i.e., DCs and P-IV.I 
cells by analyzing the activation status of proliferated T cells following co-culture with the 
respective APCs. Activated T cells are considered to upregulate CD25, CD69, and CD44 and 
to downregulate CD62L (35). Compared to peritoneal DCs, P-IV.I cells induced both OT-1 
and OT-2 T cells with less activated phenotypes (Fig. 4A). In particular, Ag-specific T cells 
stimulated by P-IV.I cells contained fewer fractions of CD25+, CD69+, or CD62L− cells than 
those stimulated by peritoneal DCs.
DCs can modulate the type of immune response through mediating the activation and 
differentiation of naïve T cells, and the type of functionally differentiated T cells are classified 
on the profiles of cytokines they secrete (38-43). To check whether peritoneal DCs induce a 
specific type of T cell response, we performed an intracellular staining of cytokines. When 
OVA-laden peritoneal APCs were cultured with CD8+ OT-1 T cells, DCs were able to generate 
a higher frequency of IFN-γ producing Tc1 cells than P-IV.I cells (Fig. 4B). However, both 
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Figure 4. Distinct differentiation of T cells by peritoneal APCs. As in Fig. 3, from mice treated with OVA Ag, peritoneal APCs, i.e., DCs and P-IV.I cells, are sorted 
by flow cytometry. Isolated 2,500 cells of respective APCs are co-cultured with 25,000 OT-1 or OT-2 T cells for 3 or 4 days respectively. (A) Proliferated T cells 
are stained and analyzed for specific markers, CD25, CD69, CD44, and CD62L. Cells with indicated phenotypes (i.e., CD25+, CD69+, CD44+, and CD62L−) and 
their respective percentages among the proliferated (i.e., CTVlo) T cells are gated and denoted in representative flow cytograms. Bar graphs are drawn from 
triplicate samples. (B, C) PMA, ionomycin and brefeldin A are treated for the last 4 h of culture. Indicated cytokines are stained intracellularly. Represented 
flow cytometric plots of live CTVlo CD8+ OT-1 (B) or CD4+ OT-2 (C) T cells are shown. Bar graphs illustrate the frequencies of described cytokine producing OT-1 
(B) and OT-2 (C) T cells among total proliferated T cells. (D) hTGF-β and/or ATRA are added to the wells containing OVA-laden APCs and OT-2 T cells. Foxp3 is 
stained intracellularly followed by the staining and fixation of surface molecules. Live CTVlo CD4+ T cells are shown, and iTreg cells are gated and denoted with 
frequencies. Representative data are shown from at least 2 independent experiments. Error bars indicate mean±SEM across multiplicate sample. 
CTVlo, low level CTV; NS, not significant. 
*p≤0.05; **p≤0.01; ***p≤0.001; ****p≤0.0001.
DCs and P-IV.I cells induced neither IL-4 producing Tc2 nor IL-17a producing Tc17 cells. In 
the co-culture with CD4+ OT-2 T cells, a higher frequency of IFN-γ+ Th1 cells was produced 
by DCs than P-IV.I cells, but IL-4 and IL-17a, the signature cytokines of Th2 and Th17 cells, 
were not detected (Fig. 4C). It is known that when Ag-laden APCs and responding naïve T 
cells are cultured under specifically conditioned media, T cells are preferentially converted 
to particular types of Tc or Th cells (28,30,33,44). Hence, we tested the culture of peritoneal 
APCs and naïve T cells under differently conditioned media (Supplementary Fig. 2). With the 
addition of LPS, both DCs and P-IV.I cells produced comparable levels of IFN-γ+ Tc1 and Th1 
cells. Similarly, both DCs and P-IV.I cells exhibited a comparable ability to induce IL-4+ Tc2/
Th2 and IL-17a+ Tc17/Th17 under pertinent conditions.
Our data indicated that T cells stimulated by P-IV.I cells possessed less activated phenotypes 
than those stimulated by DCs. Therefore, we examined whether DCs and P-IV.I cells had 
different ability to promote immunological tolerance by generating iTreg cells. DCs are 
known to induce FOXP3+ iTreg cells in vitro when cultured with naïve T cells in the media 
conditioned with TGF-β and/or ATRA (31,32). Both peritoneal DCs and P-IV.I cells rarely 
produced iTreg cells in the culture medium without any supplements (Fig. 4D). However, 
when TGF-β and/or ATRA were added to the culture media, both DCs and P-IV.I cells strongly 
iTreg cells. Especially when both TGF-β and ATRA were included in the culture, P-IV.I cells 
produced iTreg cells more potently and in a higher frequency than DCs. With both TGF-β 
and ATRA supplemented, OVA-laden P-IV.1 cells could make nearly 50% of proliferated 
OT-2 T cells differentiate into iTreg cells, which was a frequency almost twice as higher 
than peritoneal DCs iTreg cells in the same condition (Fig. 4D). Interestingly, under these 
conditions, more of the proliferated high level of CD25 OT-2 T cells induced by P-IV.I cells 
were FOXP3+ than those induced by peritoneal DCs (Fig.4D).
Influence of hematopoietic cytokines on the development of subpopulations
Since P-IV.I cells were potent peritoneal APCs expressing significant levels of CD115 
(Supplementary Fig. 3), the receptor for a key hematopoietic cytokine M-CSF, we investigated 
the role of different hematopoietic cytokines in the development of myeloid mononuclear cells 
in the peritoneal cavity. First, we examined the effect of M-CSF, GM-CSF, and FLT3L by injecting 
each hematopoietic cytokine. After 3 to 5 daily injections of the respective cytokines to mice, 
peritoneal exudate cells were harvested and analyzed (Fig. 5A). Interestingly, the administration 
of M-CSF to mice did not cause any changes in the numbers of not only CD115− DCs and LPMs 
but also CD115+ SPMs, P-IV.I, and P-IV.II cells. Meanwhile, the injection of either GM-CSF or 
FLT3L augmented the numbers of DCs and P-IV.I cells, whereas the injection of only GM-CSF, 
not FLT3L, increased the numbers of LPMs, SPMs, and P-IV.II cells. Especially, the increase in the 
number of P-IV.II cells by the injection of GM-CSF was quite dramatic (Fig. 5A).
To further verify the roles of hematopoietic cytokines tested above, we also evaluated the 
number of subpopulations in peritoneal myeloid mononuclear cells from FLT3 knockout 
(KO) and GM-CSF KO mice (Fig. 5B). In GM-CSF KO mice, no significant changes were 
observed in the numbers of all subpopulations. In FLT3 KO mice, however, the numbers of 
LPMs, DCs, and P-IV.I cells decreased while the number of SPMs increased. Unlike the other 
subpopulations, the number of P-IV.II cells was not affected in FLT3 KO mice.
Gene expression profiles of MHCII+ peritoneal myeloid mononuclear cells
To systematically analyze the differences and similarities among the 5 subsets of MHCII+ 
peritoneal myeloid mononuclear cells, including DC1 and DC2 subpopulations (Fig. 6A), RNA 
11/18https://doi.org/10.4110/in.2019.19.e15
CD11c+CD115+ Subsets in the Peritoneal Myeloid Mononuclear Cells
https://immunenetwork.org
samples were prepared from these peritoneal cell subsets and subjected to global mRNA-seq. 
The main principal components analysis identified 4 distinct clusters among the 5 subsets of 
MHCII+ peritoneal myeloid mononuclear cells (Fig. 6B); peritoneal DC1s, DC2s, and P-IV.I cells 
formed separate clusters, but SPMs and P-IV.II cells clustered indistinguishably close to each 
other. Meanwhile, P-IV.I cells clustered closer to DC2s than either DC1s or SPMs (Fig. 6B).
As expected from the result of principal components analysis above, the gene expression 
profile of P-IV.II cells was highly similar to that of SPMs. Especially, most of the macrophage 
core signature genes (45) were induced in both SPMs and P-IV.II cells (Fig. 6C). In the 
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Figure 5. Influence of hematopoietic cytokines on the development of peritoneal myeloid mononuclear subsets. Mice are injected subcutaneously with a 
hematopoietic cytokine daily for 3 (for GM-CSF) to 5 (for FLT3L and M-CSF) consecutive days. (A) Representative flow cytometric plots of peritoneal myeloid 
mononuclear subsets are shown from the mice treated with each hematopoietic cytokine. Numbers indicate frequencies of gated cells in each population. Data 
in graph are calculated from at least 3 mice, and each dot represents a mouse. (B) Numbers of cells in peritoneal myeloid mononuclear subsets are detected 
from FLT3−/− and GM-CSF−/− mice. Data in graph are calculated from at least 3 mice, and each dot represents a mouse. Error bars indicate mean±SEM across 
multiplicate sample. 
*p≤0.05; **p≤0.01; ***p≤0.001; ****p≤0.0001.
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Figure 6. Comparison of gene expression profiles of MHCII+ peritoneal myeloid mononuclear cell subsets. (A) The gating strategy to categorize peritoneal 
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meantime, P-IV.I cells were found to upregulate the expression of a significant number of 
conventional DC core signature genes (46) as similarly to peritoneal DC2s (Fig. 6D). To 
better characterize the relationship between P-IV.I cells and DC subsets, we also analyzed the 
different expressions of transcription factors involved in DC development. The expression 
of transcription factors involved in DC2 development such as RELB, IFN regulatory factor 4 
(IRF4), and neurogenic locus notch homolog protein 2 (NOTCH2) (46) were elevated in both 
DC2s and P-IV.I cells compared to DC1s (Fig. 6E). The transcription factors involved in DC1 
development such as BATF3 and IRF8 (46) were expressed more in peritoneal DC1s than DC2s 
or P-IV.I cells (Fig. 6E). Then, we also examined the expression profile of the genes associated 
with monocytes and/or monocyte-derived DCs (MoDCs) (47,48). None of the MHCII+ 
peritoneal myeloid mononuclear cell subsets expressed detectable levels of Ly6C, a monocyte 
marker, according to RNA-Seq data (data not shown). MoDCs in LPS-inflamed lymph nodes 
were found to express CD14, CD206, and CD209a (47,48). It is noticeable that both DC2s and 
P-IV.I cells expressed significantly elevated levels of CD209a compared to the other subsets, 
but the expression of CD14 and CD206 was not particularly upregulated in P-IV.I cells (Fig. 6F).
DISCUSSION
Although many investigators addressed the heterogeneity of peritoneal macrophages 
(16,17,19,49), there has been no study that clearly distinguished various subsets of DCs and 
macrophages in the peritoneal cavity. Interestingly, those studies showed the existence of 
peritoneal cells expressing the markers for both monocytes (CD115) and DCs (CD11c and MHC 
II). In the current study, we classify the peritoneal myeloid mononuclear cells into 5 subsets 
which include LPMs, DCs, SPMs, and 2 additional subpopulations with MHCII+CD11c+CD115+ 
phenotypes. The 2 subsets of MHCII+CD11c+CD115+ cells are distinguished based on their 
differential expression of CD14 and CD206. In summary, the 5 distinct populations in the 
peritoneal cavity are 1) ICAM2+F4/80hiMHCIIlo LPMs, 2) ICAM2−CD115−CD11c+MHCII+ DCs, 3) 
ICAM2−CD115+CD11c−MHCII+ SPMs, 4) ICAM2−CD115+CD11c+CD14−CD206−MHCII+ P-IV.I cells, 
and 5) ICAM2−CD115+CD11c+CD14+CD206+MHCII+ P-IV.II cells.
From a morphological point of view, LPMs, SPMs, and P-IV.II cells exhibit adherent, 
macrophage-like appearances whereas DCs and P-IV.I cells show a non-adherent, dendritic 
morphology. In terms of endocytosis and phagocytosis, LPMs are far more potent than any other 
subset. Meanwhile, SPMs and P-IV.II cells are similarly more active than DCs and P-IV.I cells in 
endocytosis and phagocytosis. Out of these 5 subsets, only DCs and P-IV.I cells are capable of 
presenting Ags and thus stimulating naïve T cells into proliferation. Besides, both DCs and P-IV.I 
cells are likewise able to induce the differentiation of T cells following their Ag presentation. In 
addition to the morphological and functional similarities, the development of DCs and P-IV.I 
cells is also influenced similarly by the hematopoietic cytokines FLT3L and GM-CSF.
As previously reported (17,19), peritoneal DCs were largely low level of CD226 and resistin-
like molecule α (RELMα) while SPMs were mainly high level of CD226 and RELMα. Our 
present study demonstrated that the expression levels of both CD226 and RELMα in P-IV.I 
cells were significantly lower than those in P-IV.II cells (Figs. 1B and 6C), implying that P-IV.I 
cells are related to peritoneal DCs and P-IV.II cells to SPMs. Our analysis of transcriptomes 
in MHCII+ peritoneal myeloid mononuclear cell subsets revealed that the expression of many 
DC signature genes, including FLT3, ZBTB46, RELB, IRF4, and NOTCH2, was elevated in 
P-IV.I cells, more closely resembling peritoneal DC2s than DC1s. In general, multidimensional 
scaling analysis of gene expression profiles indicates that P-IV.I cells are closely related to 
peritoneal DC2s, whereas P-IV.II cells are quite identical to SPMs. Previously, Bain et al. (17) 
demonstrated that the generation of peritoneal monocytes and SPMs are dependent on 
CCR2 expression in bone marrow (BM) cells; CD11c+CD115+ P-IV cells are partially dependent 
on CCR2; while peritoneal DCs are independent. Therefore, based on our gene expression 
profiles, we speculate that the generation of P-IV.II cells, like SPMs, might be dependent 
on BM monocytes in a CCR2 dependent manner. Meanwhile, the expression of CD209a, a 
marker of MoDCs, was highly induced in both peritoneal DC2s and P-IV.I cells, suggesting that 
significant fractions of both peritoneal DC2s and P-IV.I cells might consist of MoDCs.
In the present study, both DCs and P-IV.I cells were equally effective in stimulating naïve 
T cells into proliferation, but those T cells differentiated by DCs and P-IV.I cells exhibited 
different phenotypes. Especially, T cells differentiated by P-IV.I cells displayed reduced 
expression levels of CD25 and CD69 and elevated levels of CD62L, compared to those 
differentiated by DCs, indicating that the T cells proliferated by P-IV.I cells are less activated. 
Besides, P-IV.I cells are found to possess the ability to produce FOXP3+ iTreg cells better 
than peritoneal DCs. All in all, these findings highlight the possibility that P-IV.I cells are a 
distinct, tolerogenic subset of DCs in the peritoneal cavity.
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